Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus
| Autor: | E. Fernqvist-Forbes, K. Borg, T. Odergren, J. Wahren, A. Kernell, B. L. Johansson |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Blood Glucose medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Kidney Gastroenterology Nephropathy Placebos chemistry.chemical_compound Endocrinology Diabetic Neuropathies Double-Blind Method Heart Rate Internal medicine Diabetes mellitus Internal Medicine medicine Albuminuria Humans Insulin Diabetic Nephropathies Type 1 diabetes Cross-Over Studies C-Peptide C-peptide business.industry medicine.disease Peripheral neuropathy Diabetes Mellitus Type 1 chemistry Autonomic Nervous System Diseases Regular insulin Microalbuminuria business |
| Zdroj: | Diabetic medicine : a journal of the British Diabetic Association. 17(3) |
| ISSN: | 0742-3071 |
| Popis: | Summary Aims Recent studies have indicated that proinsulin C-peptide shows specific binding to cell membrane binding sites and may exert biological effects when administered to patients with Type 1 diabetes mellitus. This study was undertaken to determine if combined treatment with C-peptide and insulin might reduce the level of microalbuminuria in patients with Type 1 diabetes and incipient nephropathy. Methods Twenty-one normotensive patients with microalbuminuria were studied for 6 months in a double-blind, randomized, cross-over design. The patients received s.c. injections of either human C-peptide (600 nmol/24 h) or placebo plus their regular insulin regimen for 3 months. Results Glycaemic control improved slightly during the study and to a similar extent in both treatment groups. Blood pressure was unaltered throughout the study. During the C-peptide treatment period, urinary albumin excretion decreased progressively on average from 58 μg/min (basal) to 34 μg/min (3 months, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text